Literature DB >> 26744433

Serendipity in splendid isolation: rapamycin.

V Koneti Rao1.   

Abstract

In this issue of Blood, Bride et al report results of the first prospective multi-institutional trial of a long-term single-agent therapy for refractory cytopenias using rapamycin in 30 patients and show remarkable efficacy in children with autoimmune lymphoproliferative syndrome (ALPS).

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26744433      PMCID： PMC4705609          DOI： 10.1182/blood-2015-11-679829

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.

Authors:  S N Sehgal
Journal:  Clin Biochem       Date:  1998-07       Impact factor: 3.281

2.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

Authors:  C Vézina; A Kudelski; S N Sehgal
Journal:  J Antibiot (Tokyo)       Date:  1975-10       Impact factor: 2.649

3.  New antitumor substances of natural origin.

Authors:  J Douros; M Suffness
Journal:  Cancer Treat Rev       Date:  1981-03       Impact factor: 12.111

4.  Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency.

Authors:  Andreas G Moraitis; Lita A Freeman; Robert D Shamburek; Robert Wesley; Wyndham Wilson; Cliona M Grant; Susan Price; Stephen Demosky; Seth G Thacker; Abdalrahman Zarzour; Ronald L Hornung; Frank Pucino; Gyorgy Csako; Cheryl Yarboro; Iain B McInnes; Takashi Kuroiwa; Dimitrios Boumpas; V Koneti Rao; Gabor G Illei; Alan T Remaley
Journal:  J Clin Lipidol       Date:  2014-10-05       Impact factor: 4.766

Review 5.  Sirolimus: its discovery, biological properties, and mechanism of action.

Authors:  S N Sehgal
Journal:  Transplant Proc       Date:  2003-05       Impact factor: 1.066

6.  Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice.

Authors:  M Merle Elloso; Neal Azrolan; Suren N Sehgal; Pa-Lang Hsu; Kristen L Phiel; Caroline A Kopec; Michael D Basso; Steven J Adelman
Journal:  Am J Transplant       Date:  2003-05       Impact factor: 8.086

7.  Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.

Authors:  Karen L Bride; Tiffaney Vincent; Kim Smith-Whitley; Michele P Lambert; Jack J Bleesing; Alix E Seif; Catherine S Manno; James Casper; Stephan A Grupp; David T Teachey
Journal:  Blood       Date:  2015-10-26       Impact factor: 22.113

8.  Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer.

Authors:  Belinda Seto
Journal:  Clin Transl Med       Date:  2012-11-15

Review 9.  Approaches to Managing Autoimmune Cytopenias in Novel Immunological Disorders with Genetic Underpinnings Like Autoimmune Lymphoproliferative Syndrome.

Authors:  V Koneti Rao
Journal:  Front Pediatr       Date:  2015-07-21       Impact factor: 3.418
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.